Mainz Biomed Provides Full Year 2022 Financial Results
On April 10, 2023, Mainz Biomed (NASDAQ:MYNZ) reported a significant 130% increase in revenue from its ColoAlert product year-over-year, reaching $519,728. The company ended 2022 with a strong cash balance of $17.1 million, supporting its growth strategies. Key developments included expanding its commercial activities in Germany and Italy, acquiring exclusive rights to novel mRNA biomarkers, and progressing clinical studies aimed at enhancing colorectal cancer detection. Mainz Biomed raised $25.8 million through a follow-on share offering and appointed industry veterans to its leadership team, indicating a robust commitment to product development. Despite a growing revenue stream, the company faced substantial operating losses, amounting to $26.4 million in net losses for the fiscal year.
- Revenue from ColoAlert increased by 130% year over year to $519,728.
- Year-end cash balance was $17.1 million, providing financial stability.
- Expanded international commercial activities with five new lab partners.
- Acquired exclusive rights to five novel mRNA biomarkers.
- Raised $25.8 million through a follow-on offering.
- Net loss for the fiscal year 2022 was $26.4 million.
- Total operating expenses reached $26.7 million, significantly impacting profitability.
ColoAlert Revenue Increases
Year End Cash Balance of
BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended December 31, 2022.
“Throughout the year we operated in a position of financial strength enabling us to achieve meaningful growth across commercial, operational and product development fronts,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Heading into fiscal 2023, we have a defined set of priorities intended to facilitate our goal of becoming the leading developer of premier cancer-focused early detection and disease prevention molecular diagnostics.”
Key Highlights and 2022 Accomplishments
- Expanded international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC), including five new lab partners in Germany and Italy
- Acquired exclusive rights to five novel mRNA biomarkers which have demonstrated unique ability to identify advanced adenomas (curable precancerous polyps)
- Executed a USD 25.8 million (gross) follow-on offering of ordinary shares
- Initiated and commenced patient enrollment in European and U.S. studies (ColoFuture/eAArly DETECT) evaluating the integration of Mainz’s portfolio of proprietary and novel gene expression (mRNA) biomarkers into ColoAlert; potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC; Results from both studies expected in 2023
- Initiated ReconAAsense, U.S. Pivotal Clinical Study with Company’s CRC screening test; anticipate commencing patient enrollment in the second half of 2023
- Enhanced leadership team with appointments to Board of Directors and Company executives to lead commercial and product development groups, with former executives and senior management from Roche, Abbott, Luminex, and Qiagen; expanded Medical Advisory Board of global leaders in molecular diagnostic development
- Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer
Consolidated Statements of Financial Position
| December 31, | December 31, | |||||||||
| 2022 | 2021 | |||||||||
| ASSETS | ||||||||||
| Current Assets | ||||||||||
| Cash | $ | 17,141,775 | $ | 8,727,542 | ||||||
| Trade and other receivables, net | 259,138 | 111,842 | ||||||||
| Inventories | 175,469 | - | ||||||||
| Prepaid expenses | 801,959 | 769,825 | ||||||||
| Total Current Assets | 18,378,341 | 9,609,209 | ||||||||
| Property and equipment, net | 661,692 | 37,884 | ||||||||
| Intangible asset | - | - | ||||||||
| Right-of-use asset | 1,177,695 | 393,702 | ||||||||
| Other asset | 23,275 | - | ||||||||
| Total assets | $ | 20,241,003 | $ | 10,040,795 | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||
| Current Liabilities | ||||||||||
| Accounts payable and accrued liabilities | $ | 2,656,679 | $ | 784,786 | ||||||
| Accrued payroll | 260,000 | 233,710 | ||||||||
| Accounts payable – related party | - | 84,750 | ||||||||
| Convertible debt | 43,057 | 45,666 | ||||||||
| Convertible debt – related party | 32,181 | 32,221 | ||||||||
| Loans payable | - | 22,754 | ||||||||
| Loans payable – related party | - | 92,792 | ||||||||
| Silent partnership | 759,168 | - | ||||||||
| Silent partnership – related party | 206,167 | - | ||||||||
| Lease liabilities | 285,354 | 55,076 | ||||||||
| Total current liabilities | 4,242,606 | 1,351,755 | ||||||||
| Silent partnerships | 687,128 | 1,463,981 | ||||||||
| Silent partnerships – related party | 256,086 | 476,138 | ||||||||
| Lease liabilities | 959,116 | 387,766 | ||||||||
| Total Liabilities | 6,144,936 | 3,679,640 | ||||||||
| Shareholders’ equity | ||||||||||
| Share capital | 164,896 | 141,075 | ||||||||
| Share premium | 38,831,542 | 13,126,493 | ||||||||
| Reserve | 18,079,741 | 9,736,066 | ||||||||
| Accumulated deficit | (43,032,294 | ) | (16,644,958 | ) | ||||||
| Accumulated other comprehensive income | 52,182 | 2,479 | ||||||||
| Total shareholders’ equity | 14,096,067 | 6,361,155 | ||||||||
| Total liabilities and shareholders’ equity | $ | 20,241,003 | $ | 10,040,795 | ||||||
Consolidated Statements of Comprehensive Loss
| Years Ended December 31, | |||||||||||
| 2022 | 2021 | ||||||||||
| Revenue | |||||||||||
| ColoAlert revenue | $ | 519,728 | $ | 226,438 | |||||||
| Covid-19 and other revenue | 10,149 | 350,910 | |||||||||
| Total revenue | 529,877 | 577,348 | |||||||||
| Cost of revenue | 347,726 | 399,726 | |||||||||
| Gross profit | 182,151 | 177,622 | |||||||||
| Operating expenses: | |||||||||||
| General and administrative | 17,328,942 | (a) | 8,478,017 | (a) | |||||||
| Sales and marketing | 5,702,143 | 957,522 | |||||||||
| Research and development | 3,660,495 | 466,689 | |||||||||
| Total operating expenses | 26,691,580 | 9,902,228 | |||||||||
| Loss from operations | (26,509,429 | ) | (9,724,606 | ) | |||||||
| Other income (expense) | 122,093 | (1,965,492 | ) | ||||||||
| Income (loss) before income tax | (26,387,336 | ) | (11,690,098 | ) | |||||||
| Income taxes provision | - | - | |||||||||
| Net loss | $ | (26,387,336 | ) | $ | (11,690,098 | ) | |||||
| Foreign currency translation gain (loss) | 49,703 | 204,969 | |||||||||
| Comprehensive loss | $ | (26,337,633 | ) | $ | (11,485,129 | ) | |||||
| Basic and dilutive loss per ordinary share | $ | (1.86 | ) | $ | (1.62 | ) | |||||
| Weighted average number of ordinary shares outstanding | 14,157,492 | 7,210,889 | |||||||||
(a) General and administrative expenses included
About ColoAlert
ColoAlert®, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Gies et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert will be evaluated in the FDA-registration trial ‘ReconAAsense’. Once approved in the US, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
About Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries, please contact press@mainzbiomed.com
In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu
In the US:
Spectrum Science
Melissa Laverty/Valerie Enes
+1 540 272 6465
mainz@spectrumscience.com
For investor inquiries, please contact info@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on May 5, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly. update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What were the financial results for MYNZ for the fiscal year ended December 31, 2022?
How much cash did MYNZ have at the end of 2022?
What new partnerships did MYNZ establish in 2022?
What is ColoAlert and its significance for MYNZ?
What were the main challenges faced by MYNZ in 2022?
